RGEN
NASDAQRepligen Corporation
News · 26 weeks560%
2026-04-192026-10-11
Mix2990d
- SEC Filings12(41%)
- Insider9(31%)
- Earnings3(10%)
- Other3(10%)
- Analyst1(3%)
- Leadership1(3%)
Latest news
25 items- PRRepligen to Report Third Quarter 2026 Financial ResultsWALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its third quarter 2026 financial results on Tuesday, October 27, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the three-month reporting period ended September 30, 2026. The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 877042431. In addition, a webcast will be accessible via the Investor Relations section of the Company’s websi
- INSIDERSEC Form 4 filed by Repligen Corporation4 - REPLIGEN CORP (0000730272) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Repligen CorporationSCHEDULE 13G/A - REPLIGEN CORP (0000730272) (Subject)
- INSIDERSEC Form 4 filed by Repligen Corporation4 - REPLIGEN CORP (0000730272) (Issuer)
- SECSEC Form 8-K filed by Repligen Corporation8-K - REPLIGEN CORP (0000730272) (Filer)
- PRRepligen Completes Acquisition of BioLife SolutionsWALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN, "Repligen", or the "Company")), a life sciences company focused on bioprocessing technology leadership, today announced it has completed the previously announced acquisition of BioLife Solutions, Inc. (NASDAQ:BLFS, "BioLife")), a leading developer and supplier of cell processing tools and services for the cell and gene therapy market. "We are excited to welcome BioLife team members to Repligen," said Olivier Loeillot, President and Chief Executive Officer of Repligen. "BioLife’s highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market, adding a deeply emb
- PRFreshworks Set to Join S&P SmallCap 600NEW YORK, Oct. 5, 2026 /PRNewswire/ -- Freshworks Inc. (NASD: FRSH) will replace BioLife Solutions Inc. (NASD:BLFS) in the S&P SmallCap 600 effective prior to the open of trading on Thursday, October 8. S&P MidCap 400 constituent Repligen Corp. (NASD:RGEN) is acquiring BioLife Solutions in a deal expected to be completed soon, pending final closing conditions.Following is a summary of the change that will take place prior to the open of trading on the effective date:Effective Date Index NameCompany Name Ticker GICS Sector October 8, 2026S&P SmallCap 600Addition FreshworksFRSH Information Technology October 8, 2026S&P SmallCap 600 Deletion BioLife SolutionsBLFSHealth CareABOUT S&P DOW JONES I
- INSIDERSEC Form 4 filed by Repligen Corporation4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERCFO Garland Jason K covered exercise/tax liability with 421 shares, decreasing direct ownership by 2% to 18,408 units (SEC Form 4) (withholding tax)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERSEC Form 4 filed by Repligen Corporation4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERChief Executive Officer Loeillot Olivier exercised 5,426 shares at a strike of $141.79 and sold $976,680 worth of shares (5,426 units at $180.00) as part of a pre-agreed trading plan (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- SECRepligen Corporation filed SEC Form 8-K: Leadership Update8-K - REPLIGEN CORP (0000730272) (Filer)
- ANALYSTUBS resumed coverage on Repligen with a new price targetUBS resumed coverage of Repligen with a rating of Buy and set a new price target of $225.00
- SECSEC Form 425 filed by Repligen Corporation425 - REPLIGEN CORP (0000730272) (Subject)
- SECSEC Form 8-K filed by Repligen Corporation8-K - REPLIGEN CORP (0000730272) (Filer)
- INSIDERChief Executive Officer Loeillot Olivier covered exercise/tax liability with 2,842 shares and sold $503,506 worth of shares (3,035 units at $165.90) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 48,369 units (SEC Form 4) (withholding obligation)4 - REPLIGEN CORP (0000730272) (Issuer)
- SECSEC Form EFFECT filed by Repligen CorporationEFFECT - REPLIGEN CORP (0000730272) (Filer)
- SECSEC Form 424B3 filed by Repligen Corporation424B3 - REPLIGEN CORP (0000730272) (Filer)
- SECAmendment: SEC Form S-4/A filed by Repligen CorporationS-4/A - REPLIGEN CORP (0000730272) (Filer)
- INSIDERCHIEF ACCOUNTING OFFICER Hughes Violetta was granted 2,466 shares and covered exercise/tax liability with 277 shares, increasing direct ownership by 53% to 6,331 units (SEC Form 4) to satisfy tax liability4 - REPLIGEN CORP (0000730272) (Issuer)
- PRRepligen Corporation to Present at Wells Fargo 21st Annual Healthcare ConferenceWALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. Olivier Loeillot, President and Chief Executive Officer and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on September 9th at 1:30 p.m. ET. A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event. About Repligen Corporation Repli
- SECSEC Form S-4 filed by Repligen CorporationS-4 - REPLIGEN CORP (0000730272) (Filer)
- INSIDERChief Executive Officer Loeillot Olivier exercised 5,426 shares at a strike of $141.79 and sold $976,680 worth of shares (5,426 units at $180.00) as part of a pre-agreed trading plan (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- SECSEC Form 10-Q filed by Repligen Corporation10-Q - REPLIGEN CORP (0000730272) (Filer)
- SECRepligen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - REPLIGEN CORP (0000730272) (Filer)
RGEN FAQ
7 questionsWhat does Repligen Corporation do?
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance...Where does RGEN stock trade?
Repligen Corporation (RGEN) is listed on NASDAQ.What sector and industry is RGEN in?
Repligen Corporation operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Repligen Corporation go public?
Repligen Corporation (RGEN) completed its IPO in 1986.What are analysts saying about RGEN?
Repligen Corporation has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-09-09.What companies are similar to RGEN?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare RGEN side-by-side with any of them on Quantisnow.How can I track RGEN on Quantisnow?
Quantisnow aggregates Repligen Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RGEN to receive live email and push alerts on every new disclosure.